Novo Nordisk A/S purchases B shares worth DKK 4,109 million from Novo Holdings A/S under the 2021 share repurchase programme

Bagsværd, Denmark, 5 November 2021 - Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 4,109 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S' 2021 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 3 February 2021. The transaction price is DKK 732.48 per share and has been calculated as the three-day volume weighted average market price from 3 November 2021 to 5 November 2021 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.

Prior to the sale of B shares, Novo Holdings A/S' ownership of Novo Nordisk A/S was 28.3% of the share capital and 76.8% of the votes. Following the transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 110,519,000 B shares of DKK 0.20, corresponding to 28.1% of the capital and 76.7% of the votes in Novo Nordisk A/S.

The transaction is in line with the announcement on 3 November 2021 that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S' share capital around 28%.

In addition, transactions related to Novo Nordisk's incentive programmes have resulted in a net transfer from Novo Nordisk of 50,721 B shares in the period from 3 November 2021 to 5 November 2021.

With the transactions stated above, Novo Nordisk A/S owns a total of 28,192,626 B shares of DKK 0.20, corresponding to 1.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,310,000,000 of DKK 0.20 including treasury shares.

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:
www.novonordisk.com
CVR no:

24 25 67 90

Company announcement No 68 / 2021

Page 2 of 2

About Novo Holdings A/S
Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: www.novoholdings.dk.

About Novo Nordisk A/S
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Twitter, LinkedIn, andYouTube.

Further information

Media:
Mette Kruse Danielsen +45 3079 3883 mkd@novonordisk.com
Michael Bachner (US) +1 609 664 7308 mzyb@novonordisk.com
Investors:
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com
Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:
www.novonordisk.com
CVR no:

24 25 67 90

Company announcement No 68 / 2021

Attachments

  • Original document
  • Permalink

Disclaimer

Novo Nordisk A/S published this content on 08 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 November 2021 11:17:17 UTC.